JP6363120B2 - ベンゾオキサゼピン化合物の作製方法 - Google Patents

ベンゾオキサゼピン化合物の作製方法 Download PDF

Info

Publication number: JP6363120B2
Authority: JP; Japan
Prior art keywords: bromo; reacting; acid; prepared; methyl
Prior art date: 2013-03-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

JP2015562108A

Other languages

English (en)

Japanese (ja)

Other versions

JP2016512209A (ja

Inventor

レミアンゲラウド，

ダニエルアール．ボードリ，

ダイアンイー．カルレラ，

シャントマルホトラ，

トラヴィスレマーチュク，

フレデリクエスティー−ジーン，

Original Assignee

エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-13

Filing date

2014-03-12

Publication date

2018-07-25

2014-03-12 Application filed by エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト

2016-04-25 Publication of JP2016512209A publication Critical patent/JP2016512209A/ja

2018-07-25 Application granted granted Critical

2018-07-25 Publication of JP6363120B2 publication Critical patent/JP6363120B2/ja

Status Active legal-status Critical Current

2034-03-12 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

JP2015562108A 2013-03-13 2014-03-12 ベンゾオキサゼピン化合物の作製方法 Active JP6363120B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361779619P	2013-03-13	2013-03-13
US61/779,619		2013-03-13
PCT/EP2014/054786 WO2014140073A1 (en)	2013-03-13	2014-03-12	Process for making benzoxazepin compounds

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2017135083A Division JP6442005B2 (ja)	2013-03-13	2017-07-10	ベンゾオキサゼピン化合物の作製方法
JP2018044050A Division JP2018150298A (ja)	2013-03-13	2018-03-12	ベンゾオキサゼピン化合物の作製方法

Publications (2)

Publication Number	Publication Date
JP2016512209A JP2016512209A (ja)	2016-04-25
JP6363120B2 true JP6363120B2 (ja)	2018-07-25

Family

ID=50241450

Family Applications (6)

Application Number	Title	Priority Date	Filing Date
JP2015562108A Active JP6363120B2 (ja)	2013-03-13	2014-03-12	ベンゾオキサゼピン化合物の作製方法
JP2017135083A Active JP6442005B2 (ja)	2013-03-13	2017-07-10	ベンゾオキサゼピン化合物の作製方法
JP2018044050A Pending JP2018150298A (ja)	2013-03-13	2018-03-12	ベンゾオキサゼピン化合物の作製方法
JP2018153231A Active JP6663459B2 (ja)	2013-03-13	2018-08-16	ベンゾオキサゼピン化合物の作製方法
JP2018219226A Pending JP2019089762A (ja)	2013-03-13	2018-11-22	ベンゾオキサゼピン化合物の作製方法
JP2020032846A Pending JP2020114814A (ja)	2013-03-13	2020-02-28	ベンゾオキサゼピン化合物の作製方法

Family Applications After (5)

Application Number	Title	Priority Date	Filing Date
JP2017135083A Active JP6442005B2 (ja)	2013-03-13	2017-07-10	ベンゾオキサゼピン化合物の作製方法
JP2018044050A Pending JP2018150298A (ja)	2013-03-13	2018-03-12	ベンゾオキサゼピン化合物の作製方法
JP2018153231A Active JP6663459B2 (ja)	2013-03-13	2018-08-16	ベンゾオキサゼピン化合物の作製方法
JP2018219226A Pending JP2019089762A (ja)	2013-03-13	2018-11-22	ベンゾオキサゼピン化合物の作製方法
JP2020032846A Pending JP2020114814A (ja)	2013-03-13	2020-02-28	ベンゾオキサゼピン化合物の作製方法

Country Status (15)

Country	Link
US (1)	US9303043B2 (2)
EP (3)	EP3404032B1 (2)
JP (6)	JP6363120B2 (2)
KR (3)	KR101871133B1 (2)
CN (2)	CN108929333A (2)
AR (1)	AR095365A1 (2)
AU (3)	AU2014230812B2 (2)
BR (1)	BR112015020716A2 (2)
CA (6)	CA2897618A1 (2)
IL (1)	IL240793A0 (2)
MX (1)	MX2015011438A (2)
NZ (1)	NZ711192A (2)
RU (2)	RU2018109979A (2)
SG (2)	SG11201507394RA (2)
WO (1)	WO2014140073A1 (2)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN109293674A (zh)	2013-12-16	2019-02-01	豪夫迈·罗氏有限公司	Gdc-0032的多晶型物、其制备方法和药物用途
WO2017001658A1 (en)	2015-07-02	2017-01-05	F. Hoffmann-La Roche Ag	Benzoxazepin oxazolidinone compounds and methods of use
EP4212536B1 (en)	2015-07-02	2025-02-19	F. Hoffmann-La Roche AG	Benzoxazepin oxazolidinone compounds and methods of use
CN105906635A (zh) *	2016-06-08	2016-08-31	上海大学	全氟烷基苯并氮杂*并喹喔啉衍生物及其合成方法
CN114716377A (zh)	2016-07-29	2022-07-08	日本烟草产业株式会社	吡唑-酰胺化合物的制造方法
TW201825465A (zh)	2016-09-23	2018-07-16	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh)	2016-09-23	2018-04-16	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh)	2016-09-23	2018-05-01	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
TWI770093B (zh)	2016-12-15	2022-07-11	瑞士商赫孚孟拉羅股份公司	製備苯并氧氮呯(benzoxazepin)噁唑啶酮化合物之方法
CN108752237A (zh) *	2018-07-05	2018-11-06	四川青木制药有限公司	一种对氨基苯甲脒盐酸盐的新制备方法
JPWO2020130125A1 (ja)	2018-12-21	2021-11-04	第一三共株式会社	抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6274327B1 (en)	1992-04-13	2001-08-14	Ludwig Institute For Cancer Research	Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en)	1992-04-13	1992-05-27	Ludwig Inst Cancer Res	Polypeptides having kinase activity,their preparation and use
US5846824A (en)	1994-02-07	1998-12-08	Ludwig Institute For Cancer Research	Polypeptides having kinase activity, their preparation and use
WO2000024720A1 (en) *	1998-10-23	2000-05-04	Dow Agrosciences Llc	3-(substituted phenyl)-5-(substituted cyclopropyl)-1,2,4-triazole compounds
WO2003006151A1 (en)	2001-07-12	2003-01-23	Avecia Limited	Microencapsulated catalyst, methods of preparation and methods of use thereof
CA2463441A1 (en) *	2001-10-12	2003-05-08	Bayer Pharmaceuticals Corporation	Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
CA2627839C (en)	2005-11-02	2014-08-19	Bayer Healthcare Ag	Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
AU2007309149C1 (en) *	2006-10-23	2013-04-04	Sgx Pharmaceuticals, Inc.	Bicyclic triazoles as protein kinase modulators
CA2667453A1 (en) *	2006-10-23	2008-05-02	Sgx Pharmaceuticals, Inc.	Triazolo-pyridazine protein kinase modulators
WO2008088881A1 (en)	2007-01-19	2008-07-24	Xcovery, Inc.	Kinase inhibitor compounds
US8354528B2 (en) *	2007-10-25	2013-01-15	Genentech, Inc.	Process for making thienopyrimidine compounds
WO2009105500A1 (en) *	2008-02-21	2009-08-27	Schering Corporation	Compounds that are erk inhibitors
ES2480994T3 (es)	2008-03-31	2014-07-29	Genentech, Inc.	Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso
GB0810902D0 (en)	2008-06-13	2008-07-23	Astex Therapeutics Ltd	New compounds
ES2558742T3 (es)	2009-09-28	2016-02-08	F. Hoffmann-La Roche Ag	Compuestos inhibidores de PI3K de benzoxepina y métodos de uso
ES2570569T3 (es) *	2009-09-28	2016-05-19	Hoffmann La Roche	Compuestos de benzoxazepina como inhibidores de la PI3K y métodos de uso
US9409918B2 (en) *	2009-10-29	2016-08-09	Merck Sharp & Dohme Corp.	Bridged bicyclic piperidine derivatives and methods of use thereof
CN102558167A (zh) *	2010-12-29	2012-07-11	中国医学科学院药物研究所	Gk和ppar双重激动活性的噻唑烷二酮衍生物
WO2012126901A1 (en)	2011-03-21	2012-09-27	F. Hoffmann-La Roche Ag	Benzoxazepin compounds selective for pi3k p110 delta and methods of use
NO3175985T3 (2) *	2011-07-01	2018-04-28
WO2013182668A1 (en)	2012-06-08	2013-12-12	F. Hoffmann-La Roche Ag	Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer

2014
- 2014-03-12 JP JP2015562108A patent/JP6363120B2/ja active Active
- 2014-03-12 NZ NZ711192A patent/NZ711192A/en not_active IP Right Cessation
- 2014-03-12 CA CA2897618A patent/CA2897618A1/en not_active Abandoned
- 2014-03-12 SG SG11201507394RA patent/SG11201507394RA/en unknown
- 2014-03-12 CA CA2948765A patent/CA2948765A1/en not_active Abandoned
- 2014-03-12 KR KR1020177016062A patent/KR101871133B1/ko not_active Expired - Fee Related
- 2014-03-12 CA CA2948763A patent/CA2948763C/en not_active Expired - Fee Related
- 2014-03-12 AU AU2014230812A patent/AU2014230812B2/en not_active Ceased
- 2014-03-12 CA CA3005112A patent/CA3005112A1/en not_active Abandoned
- 2014-03-12 RU RU2018109979A patent/RU2018109979A/ru not_active Application Discontinuation
- 2014-03-12 RU RU2015138488A patent/RU2649976C2/ru not_active IP Right Cessation
- 2014-03-12 KR KR1020187016976A patent/KR20180070715A/ko not_active Withdrawn
- 2014-03-12 AR ARP140100904A patent/AR095365A1/es unknown
- 2014-03-12 BR BR112015020716A patent/BR112015020716A2/pt not_active Application Discontinuation
- 2014-03-12 EP EP18173513.5A patent/EP3404032B1/en active Active
- 2014-03-12 KR KR1020157024484A patent/KR101821468B1/ko not_active Expired - Fee Related
- 2014-03-12 CA CA3005118A patent/CA3005118A1/en not_active Abandoned
- 2014-03-12 MX MX2015011438A patent/MX2015011438A/es unknown
- 2014-03-12 CA CA3005103A patent/CA3005103A1/en not_active Abandoned
- 2014-03-12 EP EP20204345.1A patent/EP3845540A1/en active Pending
- 2014-03-12 CN CN201810489045.8A patent/CN108929333A/zh active Pending
- 2014-03-12 SG SG10201706760YA patent/SG10201706760YA/en unknown
- 2014-03-12 WO PCT/EP2014/054786 patent/WO2014140073A1/en not_active Ceased
- 2014-03-12 EP EP14709314.0A patent/EP2970329A1/en not_active Withdrawn
- 2014-03-12 CN CN201480015055.8A patent/CN105377856B/zh active Active
- 2014-03-12 US US14/205,634 patent/US9303043B2/en active Active
2015
- 2015-08-24 IL IL240793A patent/IL240793A0/en unknown
2016
- 2016-06-28 AU AU2016204432A patent/AU2016204432B2/en not_active Ceased
2017
- 2017-07-10 JP JP2017135083A patent/JP6442005B2/ja active Active
2018
- 2018-02-27 AU AU2018201393A patent/AU2018201393A1/en not_active Abandoned
- 2018-03-12 JP JP2018044050A patent/JP2018150298A/ja active Pending
- 2018-08-16 JP JP2018153231A patent/JP6663459B2/ja active Active
- 2018-11-22 JP JP2018219226A patent/JP2019089762A/ja active Pending
2020
- 2020-02-28 JP JP2020032846A patent/JP2020114814A/ja active Pending

Also Published As

Publication number	Publication date
KR20150119033A (ko)	2015-10-23
JP6663459B2 (ja)	2020-03-11
JP2016512209A (ja)	2016-04-25
EP3404032B1 (en)	2025-07-02
AU2016204432A1 (en)	2016-07-21
CN105377856B (zh)	2018-05-22
JP2019089762A (ja)	2019-06-13
CA2948765A1 (en)	2014-09-18
EP3404032C0 (en)	2025-07-02
CA2897618A1 (en)	2014-09-18
RU2018109979A (ru)	2019-02-28
NZ711192A (en)	2019-04-26
MX2015011438A (es)	2016-02-03
RU2015138488A (ru)	2017-04-20
IL240793A0 (en)	2015-10-29
CN108929333A (zh)	2018-12-04
AU2014230812A8 (en)	2015-09-10
EP3404032A2 (en)	2018-11-21
US20140275523A1 (en)	2014-09-18
CN105377856A (zh)	2016-03-02
CA2948763C (en)	2018-04-24
AR095365A1 (es)	2015-10-14
CA3005103A1 (en)	2014-09-18
JP2018008959A (ja)	2018-01-18
BR112015020716A2 (pt)	2017-07-18
RU2649976C2 (ru)	2018-04-06
JP2018150298A (ja)	2018-09-27
EP3404032A3 (en)	2019-03-13
AU2018201393A1 (en)	2018-03-15
EP2970329A1 (en)	2016-01-20
US9303043B2 (en)	2016-04-05
KR101871133B1 (ko)	2018-06-25
KR20170070270A (ko)	2017-06-21
EP3845540A1 (en)	2021-07-07
AU2014230812A1 (en)	2015-09-03
KR20180070715A (ko)	2018-06-26
CA2948763A1 (en)	2014-09-18
CA3005118A1 (en)	2014-09-18
JP6442005B2 (ja)	2018-12-19
HK1215433A1 (zh)	2016-08-26
CA3005112A1 (en)	2014-09-18
SG10201706760YA (en)	2017-10-30
AU2014230812B2 (en)	2016-04-07
KR101821468B1 (ko)	2018-01-23
AU2016204432B2 (en)	2017-12-07
SG11201507394RA (en)	2015-10-29
WO2014140073A1 (en)	2014-09-18
JP2019031493A (ja)	2019-02-28
JP2020114814A (ja)	2020-07-30

Legal Events

Date	Code	Title	Description
2015-12-28	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151203
2015-12-28	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151104
2017-01-10	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170110
2017-04-10	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170410
2017-06-08	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170608
2017-07-10	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170710
2017-07-21	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170721
2017-10-10	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171010
2018-01-09	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180109
2018-03-12	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180312
2018-05-21	TRDD	Decision of grant or rejection written
2018-05-29	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180529
2018-07-05	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180627
2018-07-06	R150	Certificate of patent or registration of utility model	Ref document number: 6363120 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2021-06-30	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2022-06-30	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2023-06-28	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2024-07-05	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2025-07-04	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250

Publication	Publication Date	Title
JP6442005B2 (ja)	2018-12-19	ベンゾオキサゼピン化合物の作製方法
CN104718212B (zh)	2017-06-16	制备噻吩并嘧啶化合物的方法
KR20160012194A (ko)	2016-02-02	이미다조피롤리디논 유도체 및 질환의 치료에서의 그의 용도
CN101528735A (zh)	2009-09-09	新的芴衍生物，包含它们的组合物和作为伴侣蛋白hsp90抑制剂的用途
EP4066895A1 (en)	2022-10-05	Compound having lysophosphatidic acid receptor agonistic activity and pharmaceutical use of said compound
HK1215433B (zh)	2019-08-23	制备苯并氧氮杂䓬化合物的方法
HK1244272B (zh)	2021-01-15	制备噻吩并嘧啶化合物的方法